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Epithelial cells are charged with protection at barrier sites, but whether this normally beneficial response might sometimes
become dysfunctional still needs definition. Here, we recognized a pattern of imbalance marked by basal epithelial cell growth
and differentiation that replaced normal airspaces in a mouse model of progressive postviral lung disease due to the Sendai
virus. Single-cell and lineage-tracing technologies identified a distinct subset of basal epithelial stem cells (basal ESCs) that
extended into gas-exchange tissue to form long-term bronchiolar-alveolar remodeling regions. Moreover, this cell subset was
selectively expanded by crossing a cell-growth and survival checkpoint linked to the nuclear-localized alarmin IL-33 that was
independent of IL-33 receptor signaling and instead connected to autocrine chromatin accessibility. This mechanism creates
an activated stem-progenitor cell lineage with potential for physiological or pathological function. Thus, conditional loss of
Il33 gene function in basal epithelial cells disrupted the homeostasis of the epithelial barrier at skin and gut sites but also
markedly attenuated postviral disease in the lung based on the downregulation of remodeling and inflammation. Thus, we
define a basal ESC strategy to deploy innate immune machinery that appears to overshoot the primordial goal of self-defense.
Our findings reveal new targets to stratify and correct chronic and often deadly postviral disease.

Introduction

Epithelial barrier sites such as skin, gut, and lungs are charged with
host protection that relies on endoderm-derived epithelial stem
cells to repair any possible damage (1–3). When the injury is due
to infection, this barrier is further responsible for a process that
contains and helps eliminate the pathogen (4, 5). For this task, barrier epithelial cells must also communicate upstream and downstream with immune cells to coordinate the host response (6–8).
If successful, a normal physiological barrier is restored in the host.
However, in some cases, barrier activities might be reprogrammed
toward a detrimental response that can result in disease. Indeed,
a relatively stereotyped pattern of epithelial injury and acute illness that progresses to epithelial remodeling and chronic disease
is well established after severe infection with respiratory viruses
(9), including epidemic influenza viruses (10). In fact, morbidity
and mortality due to respiratory viral infections often peak after
infectious virus should be cleared and tissue repair should be completed. This delayed development of lung disease after viral infecConflict of interest: MJH is founder of and equity holder in NuPeak Therapeutics
Inc. and is a member of the Data Safety Monitoring Board for AstraZeneca. KW, YZ,
SPK, BJG, and MJH are inventors on patents for MAPK inhibitors and uses thereof
(“Anti-mucus drugs and uses therefor,” patent no. WO 2014/015056 A2; “Mitogen-activated protein kinase inhibitors, methods of making and uses thereof,” patent no.
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respiratory viral infections,” patent pending).
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tion is likely a component of acute lung injury (11) but is perhaps
best established for chronic remodeling and inflammatory disease
as described for asthma (12) and previously proposed for longterm sequelae after influenza virus and coronavirus infections
(13, 14). It is therefore critical to define whether unchecked barrier cell behavior might lead to this type of postviral lung disease
(PVLD) and thereby identify targets for therapeutic correction of
an extremely common and pressing health care problem.
In that regard, several populations of lung barrier epithelial
cells (including airway basal and club cells and alveolar epithelial
type 2 [AT2] cells as well as overlapping airway-alveolar cells) are
proposed as stem cells. As a general rule, these cell populations are
active in lung development and are called up again for lung regeneration as needed in later life (3, 15–23). In support of this possibility, renewed growth of basal and AT2 cells is typically found
after viral infection in experimental models (mainly using influenza viruses) and clinical settings (including new coronaviruses;
refs. 24–27). However, the precise molecular basis for this type of
epithelial stem cell activation and its contribution to homeostatic
versus pathologic outcome still needs to be defined.
Relevant to this issue, we reported the expansion of an airway
progenitor epithelial cell population in a subset of patients with
chronic obstructive pulmonary disease (COPD) that might also
be linked to viral infection (28). This cell population expressed
markers of basal cells and tracked with high-level expression of
the cytokine IL-33 that activates the IL-33 receptor (designated
as ST2) signaling for a type 2 immune response. In turn, this type
of response can account for additional type 2 cytokine production that drives progenitor-to-mucous cell differentiation as a
1
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Figure 1. Induction of basal epithelial cell growth and differentiation genes after SeV infection. Gene-gene expression plots for RNA-Seq analysis of
lung tissue from WT mice 12 and 21 days (d) after SeV infection versus control PBS challenge. Annotations indicate 25 genes with the greatest fold change
(FC) in expression levels for SeV versus PBS (excluding immunoglobulin genes and adding informative basal epithelial cell genes, which are annotated by
colors). Data represent results from a single experiment with 3 mice per condition.

key hallmark of chronic lung disease (28–30). This detrimental outcome is likely reprogrammed from the intended purpose
of wound healing and host defense (31). However, it remained
uncertain whether similar or distinct activation of epithelial stem
cells might be (a) found after viral infection; (b) linked to tissue
remodeling and/or immune cell activation as a basis for PVLD;
or (c) controlled as a means to prevent this type of disease.
Here, we address this issue in studies of a mouse model of
PVLD caused by the natural rodent pathogen Sendai virus (SeV).
We chose this model for several reasons: (a) the pattern of acute
illness progresses from proximal to distal airspaces for a bronchiolar-alveolar (centrilobular) pattern that is characteristic of natural infection (5, 32); (b) acute infectious illness is linked to progressive and long-term lung remodeling disease in a genetically
susceptible but also widely engineered inbred strain (C57BL/6J)
(33–35); (c) these experimental conditions allow application of
highly informative single-cell, lineage-tracing, gene reporter,
and conditional gene-knockout technologies; and (d) the disease components detected to date are also routinely found in
other experimental models of inflammatory lung disease and
in humans with respiratory disease linked to viral infection (5,
8, 10, 28–30, 36). In the present study, the combination of these
advanced approaches revealed a subset of basal epithelial stem
cells (basal ESCs) that are critical for homeostasis at barrier
sites in skin and gut but are also reprogrammed for the excessive
growth, migration, and immune activation that drive postviral
disease in the lungs. Both physiological and pathological phenotypes depend on intracellular IL-33 function as a nuclear alarmin
and can be segregated from secreted IL-33 actions for a feedforward type 2 immune response that promotes basal ESC differentiation into mucous cells. This pathway also combines with basal
ESC–derived immune signaling for tissue macrophage recruitment, activation, and consequent inflammation. Our identification
of an intersection between basal ESCs and innate immunity thus
2

provides an unexpected addition to the conventional paradigm for
the actions of the epithelial barrier. The latest circuitry for basal ESC
function also defines unexpected components that can be applied to
the unmet need for a precise, disease-modifying strategy relevant to
the critical problem of PVLD.

Results

Viral infection reprograms basal ESCs for continued expansion. As
introduced above, we engaged a mouse model in which the peak
of remodeling disease occurs 49 days after SeV infection and is
well characterized at that time point using microarray-based gene
expression profiling (28). Here, we took advantage of an updated
RNA-Seq approach for unbiased whole-genome lung expression
on day 12 after SeV infection, which might represent an earlier
switch point from acute infectious illness to chronic remodeling
disease, and on day 21, when the full features of the remodeling
disease become detectable. The new analysis revealed prominent
induction of basal-epithelial cell markers 12 days after infection,
including a heretofore unrecognized increase in Aqp3 mRNA along
with conventional basal cell markers typified by Krt5, Trp63, and
Ngfr mRNA (Figure 1 and Supplemental Figure 1; supplemental
material available online with this article; https://doi.org/10.1172/
JCI149336DS1). Moreover, increases in basal cell marker levels at
day 12 continued to progress to maximal levels 21–49 days after
infection, based on RNA-Seq and the corresponding quantitative
PCR (qPCR) assay, and were correlated with subsequent mucinous differentiation marked by Muc5ac gene expression (Figure
2, A and B). This pattern of gene expression developed in concert
with bronchiolar-alveolar sites of mucinous differentiation based
on periodic acid–Schiff–hematoxylin (PAS-hematoxylin) staining
49 days after infection (Figure 2C), consistent with mucous cell
formation as reported previously (5). In concert with gene expression data, these remodeling sites also contained Aqp3+Krt5+
basal cells (Figure 3A). In bronchiolar-alveolar locations, these
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since this flow cytometry gate (EpCAM+Aqp3–) contained Sftpc mRNA as a validated AT2 cell marker
and Il33 mRNA as a possible marker for this population in mice (Supplemental Figure 2B).
Consistent with the preceding results for cell
proliferation, EpCAM+Aqp3+ cells generated lung
spheroids that maintained an Aqp3+ basal cell phenotype in 3D organoid cultures (Figure 4G) and differentiated into Muc5ac+ mucous cells in response
to IL-13 under these conditions (Supplemental Figure 2, C–E). Moreover, EpCAM+Aqp3+ cells formed
lung spheroids at higher efficiency compared with
EpCAM+Aqp3– cells (Figure 4H). Additional flow
cytometry showed that Aqp3+ cells represented a
proliferative subset of Itga6+ cells (Figure 4I and
Supplemental Figure 2, F and G), consistent with
evidence of Itga6+ basal progenitor cells in mouse
lung (19) and comparable cells in humans (28).
Indeed, flow cytometry also showed corresponding increases in Aqp3+ cells (Figure 4J), in step with
Figure 2. Basal epithelial cell expansion and mucinous differentiation after SeV infection.
cell numbers found in the lungs in situ (Figure 4K),
(A) Lung levels of mRNA markers for basal epithelial cells 0–49 days after SeV infection in
again as a subset of Itga6+ cells (Supplemental FigWT mice. (B) Corresponding mRNA marker for mucous cells under the conditions in A. (C)
ure 2H). Together, the results identified an Aqp3+
PAS and hematoxylin staining of lung sections 49 days after SeV or UV-inactivated SeV
basal ESC subset that was activated for growth in
(SeV-UV). Data represent results from a single experiment with 3–5 mice per condition, and
concert with AT2 cell hyperplasia as key long-term
experiments were replicated twice.
remodeling components in PVLD.
Single-cell analysis defines ESC subsets for postsites excluded Sftpc+ AT2 cells but still maintained podoplanin+
viral growth and differentiation. To better define virus-sensitive
epithelial cell populations, we next annotated gene expression in
(Pdpn+) cells (Figure 3, A and B). This combination was reflected
relation to lung epithelial cell expansion using single-cell RNAby Aqp3+Pdpn+ costaining in cells with basal cell morphology adjaSeq (scRNA-Seq). Gene expression patterns of lung epithelial cells
cent to Aqp3–Pdpn+ cells with AT1 cell morphology (Figure 3C).
(CD45 –CD31–EpCAM+) across 3 sample conditions (PBS control
Together, the results indicated that basal cell expansion starts in
bronchiolar sites and extends further distally to alveolar sites, as
challenge and 12 or 21 days after SeV infection) revealed 13 clussuggested for the response to influenza A virus (IAV) infection
ters of epithelial cells based on nearest-neighbor, heatmap, and
(25, 26). In parallel with this process, we also found increases in
dot plot analyses, with basal cells identified as 3 distinct cell clusSftpc+ AT2 cells in alveolar regions (Figure 3D). Bronchiolar-alveters (designated clusters 1–3; Figure 5A and Supplemental Figure
3, A and B). Gene expression for each sample condition mapped
olar remodeling was detectable on day 12 (Figure 3E) and alveolar
onto cell-type clusters and specific cell counts for each cell popremodeling as soon as 5 days after infection (Figure 3F), both of
ulation showed that basal cell cluster 3 appeared transiently on
which were reflected by the quantitation of cell markers (Figure
day 12, whereas basal cell clusters 1 and 2 were more prominent
3G) and are suggestive of distinct remodeling mechanisms for airlater, 21 days after SeV infection (Figure 5, A and B). Cell-cycle
way and alveolar compartments.
gene expression mapped onto cell-type clusters also showed a
Relevant to this observation, analysis of lung RNA-Seq data
transient appearance of basal cell cluster 3 twelve days after SeV
also showed marked increases in genes connected to cell-cycle
infection that coincided with the appearance of AT2 cell cluster 9
activation and progression, particularly 12 days but also 21 days
(Figure 5C). To relate basal cell proliferation and survival to ontogafter SeV infection (Figure 1). Consistent with these findings, we
eny, we also used scRNA-Seq data to infer cell trajectory. For this
observed increases in lung levels of Ki67 mRNA (Figure 4A) and
approach, we applied partition-based graph abstraction (PAGA)
Ki-67+ immunostaining that also peaked at 12–14 days but contin(37) for a pseudotemporal ordering algorithm followed by RNA
ued out to 49 days after infection (Figure 4, B and C, and Supplevelocity analysis of single cells, based on spliced versus unspliced
mental Figure 2A). Tissue costaining revealed further localization
mRNA abundance (38). The combined analysis revealed a parenof Ki-67 expression primarily to basal and AT2 cells (Figure 4, D
tal cluster 1 found at baseline that could give rise to cluster 3 and
and E), in agreement with the above-noted increases in these 2 cell
in turn clusters 1 and 2 to fully account for basal cell expansion
populations (Figure 3G), and confirming the delay from cell-cycle
(Figure 5D), consistent with the time course for the appearance of
activation to the change in cell numbers. Flow cytometric analysis
basal cell clusters (Figure 5, B and E) and basal cells (Figure 3G).
of lung epithelial cells (CD45 –CD31–EpCAM+) demonstrated that
To further delineate a possible basal cell program for PVLD,
cell proliferation marked by Ki-67 tracked primarily to a subset of
we mapped basal cell expansion and differentiation using cell linAqp3+ basal cells (Figure 4F). We observed smaller fold increases
eage tracing guided by Krt5 as a marker of basal cell clusters (Supin Aqp3– cells, consistent with a lower-fold expansion of AT2 cells,
J Clin Invest. 2021;131(19):e149336 https://doi.org/10.1172/JCI149336
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Figure 3. Progressive long-term lung remodeling after SeV infection.
(A) Immunostaining for Aqp3, Krt5, Sftpc, and Pdpn with DAPI counterstaining in lung sections 49 days after SeV or SeV-UV infection. Scale bar:
1 mm. (B) Immunostaining for Aqp3 and Pdpn in lung sections 0–49 days
after SeV infection. Scale bar: 1 mm. (C) Immunostaining of bronchiolar-alveolar remodeling sections under the conditions in B. Scale bar: 400
μm. Original magnification, ×3.5 (inset). (D) Immunostaining for Sftpc and
Pdpn in lung alveolar sections 0–49 days after SeV. Scale bar: 200 μm. (E)
Immunostaining for Aqp3 in lung bronchiolar-alveolar sections 49 days
after SeV infection. Scale bar: 400 μm. (F) Immunostaining for Sftpc 0–49
days after SeV infection. Scale bar: 200 μm. (G) Quantitation of immunostaining for Aqp3, Krt5, Sftpc, and Pdpn in lung sections 0–49 days after
SeV infection. Data represent results from a single experiment with 5 mice
per condition and were replicated twice.

plemental Figure 3B and Figure 5E). To validate this approach,
we first showed that Aqp3+ basal cells could be efficiently (89%)
marked by Krt5 gene expression, since FACS-purified Aqp3+ cells
were also Krt5+ when isolated from WT mice 21 days after SeV
infection (Supplemental Figure 4, A and B). We therefore tracked
the fate of Krt5-Gfp–labeled cells in post-SeV disease using lineage tracing with Krt5-Cre-Ert2 ROSA26mTmG reporter mice that
were marked with transient tamoxifen treatment 3 weeks before
infection (Supplemental Figure 4C). We found marked Krt5-GFP+
trace into airway cells, e.g., Krt5+ and Aqp3+ basal cells, Muc5ac+
mucous cells, β-tubulin IV+ ciliated cells, and Scgb1a1+ club cells,
but not into Sftpc+ AT2 cells 49 days after SeV infection (Supplemental Figure 4D). We detected no GFP signal after tamoxifen
induction without infection or with SeV infection without tamoxifen, providing for specificity of the tracing signal (Supplemental
Figure 4D). Colocalization of GFP with Aqp3 and Muc5ac immunostaining was confirmed with confocal microscopy (Supplemental Figure 4E) and quantified by image analysis (Supplemental Figure 4F). Lineage trace into Krt5+ basal cells was similar to
the response to IAV infection (25, 26), however, a Krt5 trace into
alveolar cells (as high as 72% of AT2 cells; ref. 25) after IAV was
not found after SeV infection, consistent with the preservation of
proximal-distal ontogeny found in lung development. Our detection of rare basal cells at baseline (Figure 5B) and of a parental
cluster 1 (Figure 5D) was consistent with the consequent lineage
tracing of Krt5-expressing cells with disease and the proposal for a
stem cell population poised for repair even in the adult lung.
ESC subset growth depends on an unexpected IL-33 checkpoint.
To address the role of basal cell expansion in PVLD, we considered that basal ESCs in humans are a source of IL-33 and, in
turn, that IL-33 is required for the type 2 inflammation and mucinous differentiation that is characteristic of chronic lung disease
(28). However, previous work indicated that AT2 cells, and not
basal cells, might be the predominant epithelial source of IL-33
expression after the development of PVLD in mice, based on in
situ hybridization and immunostaining (28, 35). Here, we reassessed this question more comprehensively using mice carrying
an Il33-cherry reporter cassette inserted into the endogenous Il33
gene (8), recognizing that heterozygous Il33+/– mice still manifest
all aspects of PVLD, including basal cell hyperplasia detected by
flow cytometry for EpCAM+Aqp3+ cells (Supplemental Figure 5, A
and B) and tissue immunostaining for Aqp3 in lung tissue (Supplemental Figure 5C) 21 days after SeV infection. In turn, these

mice also progressed to lung remodeling disease, as revealed by
qPCR assays for basal cell markers (Aqp3, Krt5, and Trp63), a type
2 immune response (Il33, Il13, Arg1, and Trem2), and mucinous
differentiation (Muc5ac) (Supplemental Figure 5, D–G) together
with increased mucous cell numbers, as detected by Muc5ac+
immunostaining (Supplemental Figure 5H) 49 days after SeV
infection. Relevant to the cell source for IL-33 expression, lung
immunostaining showed that the IL-33–cherry reporter localized
to Sftpc+ AT2 cells but not to Aqp3+ or Krt5+ basal cells or Scgb1a1+
club cells in Il33+/– mice 21 days after SeV infection (Supplemental
Figure 5I). Similarly, Il33+/– mice crossed with Sftpc-GFP reporter
mice showed localization of IL-33 signal in Sftpc+GFP+ AT2 cells
but not in Aqp3+ basal cells at baseline and with PVLD, as determined by flow cytometry (Supplemental Figure 5J). These findings were consistent with AT2 cells being a primary source for
secreted IL-33 and, in turn, for the stimulation of ST2-bearing
immune cells responsible for IL-13 production and the development of type 2 inflammatory disease. Moreover, the time course
for these downstream events fit with the detection of Il33 and Il13
mRNA expression in lung tissue and IL-33 and IL-13 protein production in lung tissue and bronchoalveolar lavage fluid after SeV
infection (Supplemental Figure 5, K and L).
This conventional analysis confirmed that IL-33 expression
was localized in AT2 cells at baseline and during PVLD but did
not yet assess earlier events during the peak of cell proliferation
or provide a more global and unbiased assessment of all lung epithelial cell populations. We therefore used single-cell analysis
with t-distributed stochastic neighbor embedding (t-SNE) feature
plots for a more comprehensive profile of IL-33 expression. With
this approach, we again found that Il33 gene expression was predominantly localized to AT2 cells (clusters 5–9) at baseline and
during PVLD (Figure 6, A and B). However, the sensitivity of this
approach also revealed Il33 expression in the subset of cell-cycling
basal cells (cluster 3) that appeared in concert with cycling AT2
cells (cluster 9) twelve days after SeV infection (Figure 6, A and
B). To further validate Il33 gene expression in basal epithelial cells,
we also tracked expression using IL-33–cherry reporter mice. This
approach identified an IL-33–cherry+ subset of Aqp3+ basal epithelial cells based on flow cytometric analysis (Figure 6C) and immunostaining of FACS-purified cells (Figure 6D) from Il33+/– but not
WT control mice. Further, we found a comparable IL-33+ subset of
Krt5+ cells in lung tissue at bronchiolar-alveolar remodeling sites
following immunostaining for the IL-33–cherry reporter (Figure
6E) and for IL-33 itself (Figure 6F). In each case, IL-33 was localized to nuclei in basal cells and was primarily detected 12 days
after SeV infection, corresponding to the cell proliferation peak
observed with conventional (Figure 4, A–E) and single-cell (Figure 6, A–E) approaches. The restriction of IL-33 nuclear signal to
Aqp3+ basal cells, which was maximal 12 days after infection, wsd
consistent with localization of this signal to the Il33+ cycling basal
cell cluster 3 on scRNA-Seq. This finding also raised the possibility
that IL-33 might be linked to the cell cycle in addition to its conventional role in immune signaling.
To investigate this question, we recognized that the assignment of IL-33 production primarily to AT2 cells in mice is distinct
from humans, where IL-33 expression is not detected in AT2 cells
(28). However, this difference also provided an opportunity to seg-
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Figure 4. Basal ESC growth after SeV infection. (A) Levels of Ki67 mRNA in lung tissue from WT mice 0–49 days after SeV infection. (B) Immunostaining
for Ki-67 in lung sections 12 days after SeV infection. Scale bar: 400 μm. (C) Quantitation of Ki67+ cells in lung sections 0–49 days after SeV infection. (D)
Immunostaining for Ki-67 and Aqp3 in bronchiolar-alveolar sections 12 days after SeV or SeV-UV infection. Scale bar: 200 μm. Original magnification, x3.0
(inset). (E) Immunostaining for Ki-67 and Sftpc in alveolar sections 12 days after SeV or SeV-UV infection. Scale bar: 200 μm. Original magnification, x3.2
(inset). (F) Flow cytograms for Ki-67 in lung epithelial (CD31–CD45–EpCAM+) cells (Aqp3– and Aqp3+ subsets) in WT mice 12 days after SeV or SeV-UV infection. FL2, BluFL2, empty channel. (G) Immunostaining for Aqp3 in a lung spheroid from EpCAM+Aqp3+ cells obtained 21 days after SeV infection and placed
into 3D organoid culture. Scale bar: 50 μm. (H) Number of lung spheroids from the indicated cell populations, obtained 12–49 days after SeV infection. (I)
Number of lung spheroids from the indicated cell populations, obtained 21 days after SeV infection. (J) Flow cytograms of lung epithelial cells (CD31–CD45–
restricted and analyzed for EpCAM and Aqp3) after SeV infection or PBS treatment. Values indicate the percentage of cells within each gate. (K) Numbers
of the indicated cell populations using the conditions in J. Data represent results from a single experiment with 3–5 mice per condition, and experiments
were replicated twice.

regate potential differences in IL-33 function on the basis of cell
type — in this case, basal cells versus AT2 cells. We therefore next
assessed Il33 gene function across lung epithelial cell populations
using scRNA-Seq in homozygous Il33 –/– mice compared with WT
controls for each sample condition (PBS and 12 or 21 days after
SeV infection). This analysis matrix showed a marked attenuation of basal cell expansion in Il33 –/– mice compared with WT mice
6

based on a cluster analysis of combined sample conditions (Figure
7A), number of cells per cluster in each sample condition (Figure
7B), and Krt5+ cell counts per cluster in each condition (Figure 7C)
and across all sample conditions (Figure 7D). The effect of IL-33
deficiency spared cycling basal cells in cluster 3 (and cycling AT2
cells in cluster 9) and was instead confined to basal lineage cells
in clusters 1 and 2. These findings suggested an IL-33 require-
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Figure 5. scRNA-Seq analysis of lung epithelial cells for growth and differentiation after SeV infection. (A) t-SNE plot for gene expression for single lung
epithelial (CD45–CD31–EPCAM+) cells from lungs of WT mice for combined sample conditions (12 and 21 days after SeV infection or PBS treatment). Cells
are colored according to the shared nearest-neighbor clusters, with cell types identified by marker gene expression. (B) t-SNE plots for gene expression for
each sample condition. (C) t-SNE plots for cell-cycle (G1, G2M, and S phases) gene expression for combined sample conditions. (D) Cell trajectory analysis
using combined PAGA and RNA velocity for basal cell clusters 1–3 for combined sample conditions with resolution of a parental cluster 1 subset. FA1,
ForceAtlas1; FA2, ForceAtlas2. (E) t-SNE plots for Krt5 gene expression for combined sample conditions in WT mice. Data represent results from a single
experiment with 3 mice per condition.

ment for late cell-cycle progression and subsequent cell survival
in downstream basal lineage cells. In support of this possibility,
we found decreased expression of cell-cycle genes (e.g., Cdk1 and
Pclaf1) and increased expression of apoptosis genes (e.g., Dapl1
and Psca) in basal cells in Il33–/– mice in cycling clusters relative to
WT mice (Supplemental Figure 6A). Further, this pattern of gene
regulation was not found in other epithelial cell clusters, including
cycling AT2 cells, where cell-cycle activation, but not cell-survival,
genes were inducible and dependent on IL-33 function (Supplemental Figure 6, B and C).
Given the capacity for respiratory viral infection to regulate
gene expression at the posttranscriptional level (39), we validated
our findings for the corresponding control of cell growth and survival at the protein level. Here, we found that effects at the mRNA
level were accurately reflected by corresponding decreases in active
(phosphorylated nuclear) Cdk1 and Ki-67 (marking cell-cycle activation and cell proliferation) and increases in activated caspase-3
(marking apoptosis) in lung tissue from Il33–/– mice compared with
lung tissue from WT mice (Figure 8, A and B). In contrast, the Il33
requirement for basal ESC growth found in Il33–/– mice was not
detected in mice deficient for the IL-33 receptor gene (Il1rl1–/–; Figure 8, A and B). Taken together, the findings suggested an unexpected role for intracellular versus extracellular signaling function
for IL-33 in the control of the basal cell cycle after viral infection.
To further determine Il33 gene function, we also performed
a single-cell assay for transposase-accessible chromatin (ATAC)
using sequencing (scATAC-Seq) and thereby defined chromatin
accessibility and gene promoter activation in relation to epithelial
cell clusters in WT versus Il33 –/– mice. We performed this analysis

12 days after SeV infection to capture the peak of Il33 gene activation and proliferation in basal ESCs. Under these conditions,
the analysis allowed for cell cluster assignments for scATAC-Seq
(Supplemental Figure 7A) that correlated with scRNA-Seq based
on cluster-specific markers (Supplemental Figure 7B). Further
analysis using the Integrative Genomics Viewer (IGV) showed
Krt5 (and neighboring Krt6a) gene promoter activation (adjacent
to the transcription start site) in cycling basal cells (cluster 20)
from WT mice (Supplemental Figure 7C). Moreover, this signal
was downregulated in the corresponding basal cell cluster from
Il33 –/– mice and was not found in AT2 cell clusters such as cluster 19 (Supplemental Figure 7C). In contrast, Il33 gene promoter activation was detectable in both basal cell and AT2 cell populations in WT mice but was downregulated only in basal cells
(cluster 20) in Il33 –/– mice (Supplemental Figure 7C). This finding
suggested that Il33 gene promoter activity might be sensitive to
intracellular IL-33 as we observed for cell-cycle and survival gene
expression in basal cells but not AT2 cells. This result is also consistent with differences observed in Il33 gene expression patterns
between basal cells and AT2 cells. In addition, analysis revealed
an enhancer region in cluster 20 that was also sensitive to Il33
deficiency (Supplemental Figure 7C) and was best matched to a
STAT3 transcription factor binding site in embryonic stem cells
(40). Together, scRNA-Seq and scATAC-Seq suggested that ll33
gene expression and function are distinct for cycling basal cells
and might be linked to STAT3 activation. This scheme is consistent with the EGFR/STAT3 signal transduction for cell growth
and mucinous differentiation found in the SeV mouse model and
human airway epithelial cells in culture (41).
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Figure 6. Single-cell analysis reveals IL-33
expression in a basal ESC subset linked to
the cell cycle. (A) t-SNE plots for Il33 gene
expression in WT mice for each sample condition (PBS treatment or 12 days and 21 days
after SeV infection). (B) Corresponding violin
plots for Il33 gene expression for the combined sample conditions in A. (C) Flow cytograms of lung epithelial cells based on Aqp3
and IL-33–cherry reporter expression in WT
and heterozygous Il33+/– mice for each sample
condition. Values indicate the percentage of
cells within each gate. (D) Immunostaining
for the IL-33–cherry reporter and Aqp3 for
FACS-isolated Aqp3+IL-33–
cherry+ cells under the conditions in C. Scale
bar: 50 μm. (E) Immunostaining for IL-33–
cherry and Krt5 in lung sections from Il33+/–
mice 5–49 days after SeV or SeV-UV infection.
Scale bar: 400 μm. Original magnification,
×4.4 (inset). (F) Immunostaining for IL-33
and Krt5 in lung sections from WT mice 5–49
days after SeV or SeV-UV infection. Scale bar:
400 μm. Original magnification, ×3.6 (inset).
For A and B, data represent results from a
single experiment with 3 mice per condition;
for C–F, data represent results from a single
experiment with 5 mice per condition, and
experiments were replicated twice.

Specialized IL-33 control of basal ESC subset expansion tracks
with PVLD. To further define control of basal ESC expansion in
relation to disease phenotype, we compared these 2 endpoints in
Il33 –/– and Il1rl1–/– mice. As with single-cell analysis, we detected a
marked attenuation of Aqp3+ basal cell proliferation 12 days after
SeV infection in Il33–/– mice using flow cytometry to determine
Ki-67 levels (Figure 9A and Supplemental Figure 8A). We found
that basal cell expansion was also attenuated 12 and 21 days after
8

infection, again by flow cytometry for Aqp3 (Figure 9B and Supplemental Figure 8B). We observed the same pattern for stem cell
function marked with lung spheroid formation in 3D organoid culture (Figure 9C). In contrast, these endpoints were not significantly affected in Il1rl1–/– mice (Figure 9, A–C). Consistent with these
findings, basal ESC formation of spheroids was unaffected by ST2
stimulation with IL-33 in 3D organoid cell culture (Supplemental
Figure 8C), and Il1rl1 mRNA and ST2 expression was undetect-
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Figure 7. Comparative scRNA-Seq analysis of lung epithelial cells to link IL-33 expression to the cell cycle. (A) t-SNE plot for lung epithelial cell clusters
in Il33–/– mice for combined sample conditions (12 and 21 days after SeV infection or PBS treatment). (B) Heatmap of the number of cells in each cluster for
each sample condition for WT and Il33–/– mice and the differences between these mouse strains. (C) t-SNE plots for Krt5 gene expression for each sample
condition in WT and Il33–/– mice. (D) Violin plot for Krt5 expression for the combined sample conditions in C. Data represent results from a single experiment with 3 mice per condition. *P < 0.05, by Mann-Whitney U test with Bonferroni correction.

able on epithelial cells 0–49 days after SeV infection in vivo (Supplemental Figure 8, D and E). Together, these findings provided
additional in vivo and ex vivo evidence for intracellular, but not
extracellular, IL-33 function as a requirement for epithelial stem
cell expansion. The predominant effect on Aqp3+ cells further
indicated a specific IL-33 control over the subset of basal ESCs.
We also observed intracellular IL-33 control over basal ESC
expansion in situ. In this case, Aqp3 immunostaining of lung sections showed marked attenuation in Il33–/– mice compared with
WT or Il1rl1–/– mice with preservation of IL-33–cherry+ AT2 cells
21 days after SeV infection (Figure 9D). Moreover, lung sections
showed marked attenuation of Krt5+ basal cells in Il33–/– mice but
not in Il1rl1–/– mice 49 days after SeV infection (Figure 9, E and F).
In contrast, we found that Sftpc+ AT2 cell expansion in WT mice
was unaffected in Il33 –/– and Il1rl1–/– mice (Figure 9F and Supplemental Figure 8F). In concert with the lower basal ESC levels,
Il33–/– mice manifested lower induction of lung mRNA markers
for basal cells (Supplemental Figure 9A), knockout of Il33 expression (Supplemental Figure 9B), and downregulation of markers
for the type 2 immune response (Supplemental Figure 9C) and
mucus production (Supplemental Figure 9D). Meanwhile, the levels of mRNA markers for basal cells (Supplemental Figure 9E) and
Il33-expressing AT2 cells (Supplemental Figure 9F) were unaffected in Il1rl1–/– mice, despite a disruption of type 2 immune activation
(Supplemental Figure 9G) and mucus production (Supplemental
Figure 9H). Along with changes at the mRNA level, we noted a
marked attenuation of lung histopathology in Il33 –/– mice based on

PAS staining for mucus production and hematoxylin staining for
cellularity (Supplemental Figure 9I). We confirmed these observations with a corresponding quantitative morphologic analysis
(Supplemental Figure 9J). We observed similar, albeit slightly less,
attenuation of histopathology based on PAS+ and hematoxylin+
staining in Il1rl1–/– mice (Supplemental Figure 9, I and J), indicating
the relative insensitivity of this approach for specific monitoring
of basal ESC expansion and its possible functional role in PVLD.
Indeed, we readily detected a correction of Aqp3+ basal cell expansion and bronchiolar-alveolar remodeling in Il33–/–, but not Il1rl1–/–,
mice by immunostaining (Supplemental Figure 9K). We also confirmed the lack of influence on Sftpc+ AT2 cell expansion in these
mouse strains using this approach (Supplemental Figure 9, K and
L). Correction of basal ESC expansion was associated with attenuation of airway hyperreactivity in Il33 –/– compared with WT mice
49 days after infection (Supplemental Figure 9, M and N), a sign
of functional benefit that was also not found in Il1rl1–/– mice in a
previous study (28). These findings suggest a special role for basal
ESC expansion in controlling barrier responsiveness.
Basal ESC function is required for homeostasis and PVLD. To fully
assign barrier function and/or dysfunction to IL-33–controlled
basal ESCs, we undertook a genetic strategy for selective inactivation of this cell population. Thus, we crossed Krt5-Cre-Ert2 mice
with newly generated Il33fl/fl mice (Supplemental Figure 10, A and
B) to generate Krt5-Cre-Ert2 Il33fl/fl mice for conditional deletion
of Il33 in Krt5-expressing basal cells using a tamoxifen treatment
scheme with a 3-week drug washout period (Supplemental Figure
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Figure 8. Protein-level validation of IL-33 linkage to cell-cycle activation and progression. (A) Immunostaining for phosphorylated Cdk1, as well as Cdk1,
Ki-67, and activated caspase-3 with DAPI counterstaining of lung sections from mice of the indicated strains 12 days after SeV or SeV-UV infection. Scale
bar: 200 μm. (B) Quantitation of the percentage of lung cells that stained positive for the protein markers in A. Data represent results from a single experiment with 5 mice per condition, and experiments were replicated twice. *P < 0.05, by ANOVA with Bonferroni correction.

10C). We found that tamoxifen-treated Krt5-Cre-Ert2 Il33fl/fl mice
had hair loss that did not occur in Il33–/– mice, suggesting developmental compensation in nonconditional gene-knockout mice. Hair
loss was accompanied by loss of Krt5+IL-33+ basal cells in the skin,
but not Krt5+IL-33– basal cells in the esophagus or trachea in tamoxifen-treated Krt5-Cre-Ert2 Il33fl/fl mice (Supplemental Figure 10D).
We also did not observe this phenotype in Il33–/– mice, but it could
be reproduced in Krt5-Cre-Ert2 Rosa-DTA mice with diphtheria toxin–driven loss of basal cells at all sites (Figure 10D). Disruption of
basal cell populations in skin resulted in epithelial damage
(accounting for the hair loss) and esophageal damage (resulting in
ulceration) in both Krt5-Cre-Ert2 Il33fl/fl and Krt5-Cre-Ert2 RosaDTA mice (Supplemental Figure 10E), consistent with estrogendependent control over basal cell–mediated maintenance of the
epithelial barrier at this site (42). Together, these findings suggest
that IL-33+ basal ESCs contribute to barrier maintenance under
homeostatic conditions in the skin and gut but not in the trachea.
Given the clear basal cell phenotypes of Krt5-Cre-Ert2 Il33fl/fl
mice at baseline, we applied the same protocol for tamoxifen
treatment to delete IL-33–dependent basal cells followed by a
3-week washout period leading up to viral infection (Figure 10A).
Under these conditions, neither tamoxifen-treated nor untreated
Krt5-Cre-Ert2 Il33fl/fl mice showed significant differences in the
clinical signs or weight loss that develop after SeV infection (Figure 10B) or in lung levels of SeV-NP RNA (Figure 10C). However,
the usual Aqp3+ basal cell expansion 21 days after SeV infection
10

as monitored by flow cytometry was significantly attenuated in
tamoxifen-treated Krt5-Cre-Ert2 Il33fl/fl mice (Figure 10D). There
was no significant change in the corresponding increases in Aqp3–
cells (in a gate that included AT2 cells), thus confirming the treatment’s specificity (Figure 10D). Similarly, basal cell proliferation
(based on Ki-67 immunostaining; Figure 10E) and consequent cell
numbers (based on Krt5 immunostaining; Figure 10F) were markedly downregulated, without affecting the expression of comparable markers of AT2 cells (Figure 10G) in tamoxifen-treated
mice, as confirmed by quantitative morphology (Figure 10H).
Tamoxifen-treated mice also showed a marked downregulation of
mRNA markers of basal cells (Figure 11A), with no effect on the
expression of the AT2 cell marker IL-33 (Figure 11B), still attenuated expression of markers of type 2 inflammation (Figure 11C)
and mucus production (Figure 11D), and the associated lung histopathology (Figure 11, E and F). In addition, the usual Aqp3+Pdpn+ cell accumulation in bronchiolar-alveolar remodeling regions,
but not the associated Sftpc+ AT2 hyperplasia in alveolar sites, was
also markedly decreased 49 days after infection (Figure 11, G and
H). In line with a correction of the cellular phenotypes of disease,
we also found functional improvements marked by corrections in
blood oxygen desaturation (Figure 11I) and airway hyperreactivity
(Figure 11J) in tamoxifen-treated, basal cell–depleted mice compared with control mice 49 days after SeV infection.
A distinct feature of Krt5-Cre-Ert2 Il33fl/fl mice was the capacity for attenuation of PVLD despite a preserved induction of Il33
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Figure 9. IL-33–dependent basal ESC expansion in PVLD. (A) Proliferation levels determined by flow cytometry of lung epithelial cells based on Ki-67
expression for WT versus Il33–/– and Il1rl1–/– mice 12 days after SeV versus SeV-UV infection. (B) Corresponding cell numbers from flow cytometry of lung
epithelial cells based on Aqp3 and EpCAM expression 12 and 21 days under the conditions in A. (C) Corresponding day-21 lung spheroid formation for
FACS-purified cell populations under the conditions in A. (D) Immunostaining for Aqp3 and the IL-33–cherry reporter (cherry) in lung sections under the
conditions in A. Scale bar: 200 μm. (E) Immunostaining for Krt5 in lung sections 49 days after SeV or SeV-UV infection under the conditions in A. Scale bar:
1 mm. (F) Quantitation of Krt5 and Sftpc staining under the conditions in E. Data represent results from a single experiment with 3–8 mice per condition,
and experiments were replicated twice. *P < 0.05, by ANOVA with Bonferroni correction.

expression (Figure 11B). This combination was distinct from disease blockade in Il33 –/– mice, raising the possibility that basal cells
might be activated to also influence IL-33–responsive immune
cells. Indeed, macrophage accumulation marked by F4/80 immunostaining was significantly attenuated in lung sections from
tamoxifen-treated versus untreated Krt5-Cre-Ert2 Il33fl/fl mice

(Figure 12, A and B). Moreover, the pattern of macrophage accumulation resembled the localized sites of basal cell expansion and
remodeling (based on similar regional changes shown in Figure
10F, Supplemental Figure 9, I and K, and Figure 12A). As a basis
for this effect, scRNA-Seq revealed that the macrophage chemokine Cxcl17 was induced primarily in basal cells and the basal cell–
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Figure 10. Selective basal ESC depletion in PVLD. (A)
Protocol scheme for analysis of Krt5-Cre-Ert2 Il33fl/fl mice
with or without tamoxifen (Tam) treatment followed by SeV
infection. (B) Body weights of mice under the conditions in
A. (C) Lung levels of SeV-NP RNA in mice under the conditions in A. (D) Cell numbers determined by flow cytometry of
lung epithelial cells based on Aqp3 and EpCAM expression
after 21 days under the conditions in A. (E) Immunostaining
for Ki-67 plus Aqp3 or Sftpc in lung sections from Krt5Cre-Ert2 Il33fl/fl mice after 12 days under the conditions in
A. Scale bars: 400 μm and 100 μm (enlarged insets). (F)
Immunostaining for Krt5, 49 days after SeV infection for
the conditions in A. Scale bar: 1 mm. (G) Immunostaining
for Sftpc and IL-33 under the conditions in F. Scale bar: 400
μm. (H) Quantitation of staining for the conditions in E and
F. Data represent results from a single experiment with 4–5
mice per condition, and experiments were replicated twice.
*P < 0.05, by ANOVA with Bonferroni correction.
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derived lineage (Figure 12C). Thus, Cxcl17 mRNA levels were 100fold higher in the basal cell lineage than in the AT2 cell lineage.
In addition, lung levels of Cxcl17 were attenuated (Figure 12D) in
the same pattern as for macrophage accumulation (Figure 12B).
Further, mRNA induction identified with scRNA-Seq of EpCAM+
epithelial cells was linked to Cxcl17 protein expression localized to
Aqp3+ bronchiolar and bronchiolar-alveolar remodeling regions in
lung sections 49 days after SeV infection (Figure 12E). Together,
the findings establish basal ESC capabilities of homeostatic function at epithelial barrier sites in skin and gut under baseline conditions but, alternatively, of remodeling and inflammatory disease
activities at a corresponding barrier site in the lung after respiratory viral infection.

Discussion

To address the role of barrier epithelial cells in host protection versus disease, we performed comprehensive single-cell and transgenic analyses of a mouse model of lung disease that develops
after a characteristic centrilobular pattern of infection with a natural respiratory pathogen. We compared the findings with barrier
behavior at baseline without infection in lung, skin, or gut sites.
The combined approach identified a distinct subset of basal ESCs
that maintain skin and gut barriers under normal conditions and
instead orchestrates remodeling and inflammatory disease in the
lung after severe viral infection. In both cases, basal ESCs cross
an IL-33–linked checkpoint for cell growth and survival. In the
case of viral infection in the lung, a subset of basal ESCs engaged
this mechanism to jump the usual bronchiolar-alveolar junction
and grow into contiguous airspaces as a new site for mucinous
differentiation and immune activation. The mouse model was
critical to defining each of these homeostatic and pathologic
components and especially to segregating intracellular versus
extracellular IL-33 function in barrier epithelial cell activities as
depicted in a summary scheme (Figure 13). Here, we developed
4 key points in this scheme derived from these observations and
provide the relevance to barrier maintenance and postviral disease in general, given the overlap with phenotypes across a broad
spectrum of lung diseases linked to respiratory viral infections (5,
10–14, 27, 28, 36, 41, 43).
The first of these 4 points relates to the understanding of epithelial cell hyperplasia as a characteristic feature of the response
to respiratory viral infection. In mouse models of IAV infection,
others recognized that basal epithelial cell hyperplasia could
extend to alveolar sites (24) and might reflect a basal progenitor–
to–alveolar daughter cell pathway for alveolar repair and functional improvement (25). Related work on the IAV model showed
that basal cell expansion might depend on Notch signaling and
yield suboptimal alveolar repair (26, 44), whereas another study
of IAV found that Wnt-responsive alveolar epithelial progenitor
cells within the AT2 cell lineage might be responsible for alveolar regeneration (45). Here, we examined the SeV model to
address each of these issues and found that (a) subsets of both
basal and AT2 cells were activated for long-term hyperplasia
after viral infection; (b) the activated basal cell lineage was not
traced into AT2 cells, perhaps consistent with studies of lung
development and injury that preserve the bronchiolar-alveolar
junction (23, 46); (c) basal cell hyperplasia extended with time to

bronchiolar-alveolar sites and was not associated with upregulation of Notch pathway components based on genomic analyses;
(d) AT2 cells were absent from bronchiolar-alveolar remodeling
sites, whereas AT2 cell hyperplasia developed at separate alveolar remodeling sites; (e) segregated basal and AT2 cell expansion
sites fit with a distinct molecular control of these cell populations
vis à vis growth and survival requirements for IL-33 function; and
(f) selective blocking of basal ESC activation via conventional
or conditional loss of Il33 gene function improved remodeling
(including mucinous differentiation), inflammation (including
macrophage infiltration), and function (including hyperreactivity and hypoxia) as readouts of PVLD. Together, these findings
reveal the independent nature of basal and AT2 cell hyperplasia
and the consequent remodeling and repair endpoints. Whether
this paradigm might differ for IAV infection still needs to be
defined, but it nonetheless provides mechanistic guidance for
generally descriptive single-cell data in humans with lung disease (47) as discussed further below.
The second key point of our work also relates to the question
of mechanism, as we identified a basal ESC requirement for the
nuclear alarmin IL-33 in cell growth and survival in baseline conditions and after viral infection. This connection was unexpected, given the conventional view of IL-33 as an extracellular cytokine that signals to its ST2 receptor for a type 2 immune response
charged for tissue repair (48–51). The alternative possibility of
a nuclear signal was proposed in cell culture studies of nuclear
IL-33 binding to mitotic chromatin and the regulation of gene
transcription via histone modification and transcription factor binding (52–54). Another report discounted this function in
endothelial cell cultures (55), but none of these previous studies
focused on airway epithelial cells or viral infection, nor did they
take advantage of any cell-type differences in IL-33 function.
Here, we identified a role for nuclear IL-33 based on several lines
of evidence: (a) Il33 but, not Il1rl1, gene knockout resulted in the
attenuation of basal cell activation of growth and survival genes;
(b) the localization of IL-33 to basal cell nuclei corresponded in
space and time to basal cell activation; (c) the effect of IL-33 on
basal cells was maximal when secreted IL-33 levels were still
undetectable; and (d) Il33 gene knockout resulted in loss of the
expected chromatin accessibility signal selectively in a cycling
population of basal epithelial cells. Together, these findings are
most compatible with the idea that IL-33 exerts nuclear control of
cell-cycle activation and cell survival via autocrine signaling that
is separate from extracellular ST2 activation via paracrine signaling. Additional work is needed to link IL-33 to specific interactions with nuclear proteins and epigenetic modification as a basis
for immune training of basal ESCs, as found in innate immune
cells. However, our data on chromatin accessibility at the Il33
gene promoter and enhancer regions (including the potential
for STAT3-binding sites) provide a roadmap for addressing the
regulation of IL33 and IL-33 target genes. Our study showing
that nuclear IL-33 function is required for basal but not AT2 cell
growth provides an initial molecular basis for distinct responses
of these cell populations to lung injury.
The third notable point of our findings relates to the interaction of basal ESCs with immune cell partners. As discussed
above, previous work highlighted the role of macrophages
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Figure 11. Basal ESC requirement for gene expression, remodeling, and
functional readouts for PVLD. (A–D) Levels of mRNA markers for basal cells
(A), AT2 cells (B), type 2 immune response (C), and mucus production (D), 49
days after SeV or SeV-UV infection in Krt5-Cre-Ert2 Il33fl/fl mice with or without tamoxifen treatment. (E) PAS and hematoxylin staining of lung sections
for the conditions in A. Scale bar: 1 mm. (F) Quantitation of staining of lung
sections in E. (G) Immunostaining for Aqp3 and Pdpn under the conditions
in A. Scale bar: 1 mm. (H) Immunostaining for Sftpc and Pdpn under the
conditions in A. Scale bar: 200 μm. (I) Oximeter levels for blood oxygen saturation (SpO2) under the conditions in A. (J) Values for airway resistance (RRS)
at baseline and after inhaled MCh under the conditions in A. Data represent
results from a single experiment with 5 mice per condition, and experiments
were replicated twice. *P < 0.05, by ANOVA with Bonferroni correction.
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Figure 12. Basal ESC immune-signaling function in PVLD. (A) Immunostaining for F4/80 on day 49 after SeV or SeV-UV infection of Krt5-Cre-Ert2
Il33fl/fl mice with or without tamoxifen treatment. Scale bar: 1 mm. (B) Quantitation of staining for the images in A. (C) Dot plot for Cxcl17 gene
expression from scRNA-Seq analysis of lung epithelial cells for combined sample conditions (12 and 21 days after SeV infection or PBS challenge). (D)
Lung levels of Cxcl17 mRNA for the conditions in A. (E) Immunostaining for Cxcl17 and Aqp3 in lung sections after 49 days under the conditions in A.
Scale bar: 400 μm. Data represent results from a single experiment with 5 mice per condition, and experiments were replicated twice. *P < 0.05, by
ANOVA with Bonferroni correction.

(including IL-33/ST2 signaling to macrophages) in tissue repair
(48–51). However, an alternative pathway toward remodeling
disease was less certain. In that regard, recent studies of SeV
infection serve to establish distinct roles for innate lymphoid
(ILC2) and myeloid (tissue macrophage and monocyte-derived
DC [moDC]) contributions to PVLD (8, 35). Our results add that
IL-33+ basal cells might be key to recruiting macrophages and
DCs and might do so by induction of Cxcl17, a chemokine gene
first identified on the basis of lung mucosal expression and function in mice and humans (56, 57). Indeed, we found that Cxcl17
induction and macrophage accumulation marked bronchiolaralveolar remodeling regions in PVLD. In addition to downstream
effector signals for macrophage infiltration, recent work also
identifies moDCs that are virus activated to provide an upstream
immune cell niche for AT2 cells after viral infection (35). This
effect would generally be attributed to an effect on cell growth
and/or survival, but a signal for epithelial cell movement to distal
airspaces might also be critical in the case of basal ESCs. Indeed,
other chemokines (notably CCL5) can provide both survival and
migration signals to airway epithelial cells and macrophages
after respiratory viral infection in mouse and human models (6).
Therefore, it will be of interest to further define function and
track the expression of Cxcl17 and as-yet undefined niche components in PVLD in mouse models and humans.
To extend this point, the fourth implication of our study derives
from the translation of experimental data to clinical conditions
exemplified by lung conditions ranging from acute lung injury
to chronic remodeling disease. As noted above, our paradigm for
PVLD appears to hold in varying forms across a broad sample of
RNA viruses (IAV, SeV, enterovirus D68 [EV-D68], respiratory
syncytial virus [RSV], human rhinovirus [HRV], and severe acute
respiratory syndrome–coronavirus [SARS-CoV]) studied in our
laboratory and others’ (5, 10, 58–60). The present data therefore

link acute viral pneumonia to chronic bronchiolization, as suggested in descriptive reports of presumed viral infection (11) and
documented SARS-CoV-2 infection (27, 43). Similarly, the recently
reported proteomic expression of CTSL1 in COVID-19 lung tissue
(61) and TNFRSF12A in basal cell–derived organoids (62) was also
identified in our SeV model (in basal cell cluster 2), thus assigning
a cell location in vivo and again underlining the stereotyped epithelial cell response to severe respiratory viral infections. The data
also fit with the capacity of basal progenitor cell clones to cause
inflammation, fibrosis, and mucinous differentiation when transplanted from patients with lung disease into mouse lung (63). Here,
we proved this concept in vivo with the identification of a subset of
basal ESCs that were modified by viral infection as a requirement
for lung remodeling disease in experimental models designed to
mimic the features of PVLD in humans. Studies are needed and are
currently underway to determine whether similar cell and molecular events might be found after influenza virus and coronavirus
infection in animal models and humans.
In summary, we anticipate that our findings will provide a new
perspective on epithelial barrier function and a mechanistic basis
for marking and correcting PVLD. To place the present findings in
perspective, we recognize that mucociliary removal and epithelial wound responses represent some of the most ancient systems
for defending against environmental injury. However, there might
also be sufficient evolutionary pressure for an innate walling-off
response that it can transform to drive remodeling disease under
some circumstances. Thus, the present paradigm connects the primordial role of the epithelial barrier to the aberrant disease process found in susceptible hosts based on specific cell and molecular events. As an example, stress kinases such as MAPK13 might
regulate both epithelial cell growth and mucinous differentiation
and might therefore provide a suitable target for intervention and
for defining additional factors that regulate progressive tissue
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Figure 13. Scheme for the role of basal ESCs in PVLD. Key steps include (A) lung injury due to acute viral infection with damage to bronchiolar and alveolar
epithelial cells and (B) lung remodeling with basal ESC growth linked to nuclear IL-33 (nIL-33) control of cell growth and survival in concert with IL-33–
independent AT2 cell growth. Subsequent production of Cxcl17 and secreted IL-33 (sIL-33) drives tissue macrophage (Mac) and ILC2 production of IL-13 for
type 2 inflammation and mucinous differentiation. Together, these events result in local epithelial cell hyperplasia at bronchiolar and alveolar sites and, in
turn, basal ESC migration and further growth and differentiation at bronchiolar-alveolar remodeling sites (generally designated as bronchiolization). These
events are based on the present mouse model, recognizing that AT2 cells are not a significant source of IL-33 in humans, where intracellular and extracellular functions of IL-33 might be combined in basal cells.

remodeling (64). The markers for the relevant basal ESC subset
identified in our study thus provide a roadmap for a precise, disease-modifying strategy relevant to the pressing and widespread
consequences of severe respiratory viral infections.

Methods

Details on mouse line generation and treatment, RNA-Seq analysis,
real-time qPCR assay, immunohistochemistry and immunocytochemistry, flow cytometry and FACS, epithelial cell culturing, scRNA-Seq
analysis, scATAC-Seq analysis, and lung function testing are provided
in the Supplemental Methods.
Data availability. The RNA-Seq and scRNA-Seq data were deposited in the NCBI’s Gene Expression Omnibus (GEO) database (GEO
GSE180392, RNA-Seq; GSE178517, scRNA-Seq; GSE178711, scATAC-Seq).
Study approval. All mouse husbandry and experimental procedures
were approved by the Animal Studies Committees of the Washington
University School of Medicine, in accordance with NIH guidelines.
Statistics. All data presented are expressed as the mean ± SEM. For
these data, statistical differences between means for sample conditions
were assessed using 1-way ANOVA with Bonferroni correction for multiple comparisons. For violin plot formats of single-cell gene expression
data, statistical differences between the means for sample conditions
were assessed using a Mann-Whitney U test with Bonferroni correction
for multiple comparisons. For all data, the significance threshold was set
at a P value of less than 0.05. The number of mice for each condition and
the number of replicate experiments are indicated in the figure legends.
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